This website requires Javascript for some parts to function propertly. Your experience may vary.

Hengeler Mueller advises Paragon Partners on voluntary public purchase offer for APONTIS PHARMA | Hengeler Mueller News

Hengeler Mueller advises Paragon Partners on voluntary public purchase offer for APONTIS PHARMA

APONTIS PHARMA and Zentiva Group have signed an investor agreement on the basis of which Zentiva Group will launch a voluntary public purchase offer for the shares of APONTIS PHARMA. In this context, funds advised by Paragon Partners have entered into a purchase agreement for the sale of an approx. 37.5% stake in APONTIS PHARMA to Zentiva Group.

Hengeler Mueller is advising Paragon Partners on the transaction.

Hengeler Mueller team for Paragon

M&A/Corporate: Martin Ulbrich, Oda Christiane Goetzke (both lead, partner, Düsseldorf), Jasmin Atta-Schumacher, Tim Jaeger (both associates, both Düsseldorf),

Regulatory: Jan Schülting (senior associate, Düsseldorf),

Antitrust:  Philipp Otto Neideck (partner, Düsseldorf).

Latest Articles

BRUSSELS À JOUR: Foreign Subsidies Regulation - a Year of Mandatory Notifications in Review

Competition Law in the Digital Age - Newsletter October 2024

BRUSSELS À JOUR – LA RENTRÉE 2024: Fall Forecast: Key Competition Law Developments You Need to Know After the Summer Break

Recent Mergers & Acquisitions Work